<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	Yes, in materials and methods P.6 line: 162-184.	
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	No cell line is used in the study	N/A
Provide accession number in repository OR	No cell lille is used in the study	NA
supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of		N/A
origin, genetic modification status.		
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	No laboratory animals are involved in the study	N/A
genetic modification status. Provide accession		
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the		N/A
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number		N/A
in repository (where relevant) OR RRID		
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession	No plants and microns were involved in the study.	N/A
number if available, and source (including location		
for collected wild specimens)		
Microbes: provide species and strain, unique		N/A
accession number if available, and source		
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Page 5, lines 155-158; Page 17, lines 523-528	11/ 4
equivalent committee(s), provide reference number	rage 5, mes 155-156, rage 17, mes 525-526	
for approval.		
Provide statement confirming informed consent	Page 5, lines 155-158; Page 17, lines 523-528	
obtained from study participants.	1 age 3, miles 133-130, r age 17, miles 323-320	
Report on age and sex for all study participants.	Age was missing for some patients in the screened	N/A

<u>Design</u>

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration	This is not a clinical trial.	N/A
number OR cite DOI in manuscript.		
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	No detailed protocol was cited.	N/A
by-step protocols are available.		,,,
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been		
done, or if they were not carried out.		
Sample size determination		N/A
Randomisation		N/A
Blinding		N/A
Inclusion/exclusion criteria		N/A
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	No wet lab experiments were conducted	N/A
Define whether data describe technical or biological	No wet lab experiments were conducted	N/A
replicates		
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 5, lines 155-158; Page 17, lines 523-528	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Not involved	N/A
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Not involved	N/A
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,		N/A
state the authority granting approval and reference		

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		N/A
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Page 7-8, lines 221-227	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Data availability form has been filled	
If data are publicly available, provide accession number in repository or DOI or URL.	Data will be available upon request.	N/A
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Public data were downloaded from https://www.cbioportal.org	
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	Line 221-227	
If code is publicly available, provide accession number in repository, or DOI or URL.		N/A

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal	
ARRIVE) have been followed, and whether a checklist	follows ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article Information: http://dx.doi.org/10.21037/atm-20-5118